Description

Ercanetide (developmental code NNZ-2591; CAS 847952-38-9) is a synthetic analogue of cyclic glycine-proline (cGP) designed to enhance neuroprotection. With a molecular formula of C??H??N?O? and molecular weight ~194.23 Da, this white to off-white solid is produced under GMP conditions with 99.98% purity—ensuring top-tier consistency for research use.

Preclinical studies demonstrate that oral or intracerebroventricular administration of Ercanetide significantly reduces brain tissue damage following hypoxic-ischemic injury. In rat models, it improves motor function post-injury and alleviates memory impairment induced by scopolamine.

Product Specifications

Mechanism of Action & Research Applications

Ercanetide works by stabilizing neural tissue and reducing ischemic damage. In preclinical models, oral or centrally administered Ercanetide enhanced motor function, preserved neuronal density, and mitigated hippocampal and cortical tissue damage post-hypoxia or scopolamine challenge.

This makes it a valuable tool in research areas such as neuroprotection, stroke, neurodevelopmental disorders (e.g., Angelman syndrome), and memory impairment studies.

Disclaimer

This product is strictly for laboratory research use only. It is not approved for human or veterinary use. Handle in accordance with institutional safety protocols.